Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer

References

• Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J. Clin.55, 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Voldborg BR, Damstrup L, Spang-Thomsen M et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol.8, 1197–1206 (1997).
   PubMed Web of Science ®Google Scholar
• Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumour Biol.21, 105–115 (2000).
   PubMed Web of Science ®Google Scholar
• Ranson M. Technology evaluation: ABX–EGF, Abgenix/Amgen. Curr. Opin. Mol. Ther.5, 541–546 (2003).
   PubMed Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res.59, 1236–1243 (1999).
   PubMed Web of Science ®Google Scholar
• Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell61, 203–212 (1990).
   PubMed Web of Science ®Google Scholar
• Caraglia M, Marra M, Meo G, Addeo SR, Tagliaferri P, Budillon A. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy. Recent Pat. Anticancer Drug Discov.1(2), 209–222 (2006).
   PubMedGoogle Scholar
• Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX–EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy. Crit. Rev. Oncol. Hematol.38, 17–23 (2001).
   PubMed Web of Science ®Google Scholar
• Adams R, Maughan T. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Rev. Anticancer Ther.7, 503–518, (2007).
   PubMed Web of Science ®Google Scholar
• Esteller M, Gonzalez S, Risques RA et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J. Clin. Oncol.19, 299–304 (2001).
   PubMed Web of Science ®Google Scholar
• De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol.19(3), 508–515 (2008).
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26, 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol.27(12), 2091–2096 (2009).
   PubMed Web of Science ®Google Scholar
• Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol.26, 5705–5712 (2008).
   PubMed Web of Science ®Google Scholar
• Mitchell EP, Perez-Soler R, Van Cutsem E et al. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology21, 4–9 (2007).
   PubMedGoogle Scholar
• Humblet Y, Peeters M, Siena S et al. Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab). American Society of Clinical Oncology, Chicago, IL, USA (2007) (Abstract 4038).
   Google Scholar
• Michelini T, Hecht JR, Peeters M et al. Pooled analysis of five clinical trials examining the predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC). American Society of Health-System Pharmacists, Las Vegas, NV, USA (2007) (Abstract P141D).
   Google Scholar
• Mancl EE, Kolesar JM, Vermeulen LC. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Am. J. Health Syst. Pharm.66(23), 2105–2112 (2009).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX–EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol.22, 3003–3015 (2004).
   PubMed Web of Science ®Google Scholar
• Weiner LMBA, Rowinsky E, Crawford J et al. Updated results from a dose and schedule study of panitumumab (ABX–EGF) monotherapy, in patients with advanced solid malignancies. Presented at: ASCO Annual Meeting Proceedings. J. Clin. Oncol.23, (2005) (Abstract 3059).
   Google Scholar
• Hecht JR, Patnaik A, Berlin J et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer110, 980–988 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer. J. Clin. Oncol.25, 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S et al. A Phase III randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): subset analyses in elderly pts and in pts with poor performance status. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA 19–21 January 2007.
   Google Scholar
• Humblet Y, Peeters M, Siena S et al. Association of skin toxicity (ST) severity with clinical outcomes and health related quality of life (HRQoL) with panitunumab (Pmab). J. Clin. Oncol.25, (2007) (Abstract 4038).
   Google Scholar
• Mitchell EP, Hecht JR, Baranda J et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis. J. Clin. Oncol.25, 408 (2007).
   Google Scholar
• Hecht J, Posey J, Tchekmedyian S et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). Presented at: Gastrointestinal Cancers Symposium. San Francisco, CA, USA 26–28 January 2006.
   Google Scholar
• Schwartzberg LS, Hurwitz H, Stephenson J et al. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). Presented at: ASCO Annual Meeting Proceedings. J. Clin. Oncol.25, (2007) (Abstract 4081).
   Google Scholar
• Peeters M, Van Cutsem E, Berlin J et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. Presented at: ASCO Annual Meeting Proceedings. J. Clin. Oncol.25, (2007) (Abstract 4138).
   Google Scholar
• De Roock W, Piessevaux H, De Schutter J et al.KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol.19(3), 508–515 (2008).
   PubMed Web of Science ®Google Scholar
• Wainberg Z, Hecht JR. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin. Biol. Ther.6, 1229–1235 (2006).
   PubMed Web of Science ®Google Scholar
• Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J. Clin. Oncol.25, 4057–4065 (2007).
   PubMed Web of Science ®Google Scholar
• Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol.27(5), 672–680 (2009).
   PubMed Web of Science ®Google Scholar
• Marshall JL. Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: synergy or antagonism? J. Oncol.2009, 937305 (2009).
   PubMedGoogle Scholar
• Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor – targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst.101, 1308–1324 (2009).
   PubMedGoogle Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ et al. Kras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359, 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• García-Sáenz JA, Sastre J, Díaz-Rubio García E. Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. Clin. Transl. Oncol.11(11), 737–747 (2009).
   PubMedGoogle Scholar
• Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer120, 781–787 (2007).
   PubMed Web of Science ®Google Scholar
• Caraglia M, Tagliaferri P, Correale P et al. Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb. Cancer Immunol. Immunother.37(3), 150–156 (1993).
   PubMedGoogle Scholar
• Caraglia M, Pinto A, Correale P et al. 5-Aza-2’-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. Ann. Oncol.5(3), 269–276 (1994).
   PubMed Web of Science ®Google Scholar